IgG N-糖基化修饰在糖尿病视网膜病变中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.03.509

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (3): 509-513.doi: 10.16352/j.issn.1001-6325.2023.03.509

IgG N-糖基化修饰在糖尿病视网膜病变中作用的研究进展

张艺馨¹, 蔡善君^1*, 李智立², 于伟泓³, 张华^4*

1.遵义医科大学附属医院眼科,贵州遵义 563003;
2.中国医学科学院基础医学研究所北京协和医学院基础学院生物物理及结构生物学系,北京 100005;
3.中国医学科学院北京协和医学院北京协和医院眼科;
4.继续教育学院,北京 100730

收稿日期:2022-04-02 修回日期:2022-10-17 出版日期:2023-03-05 发布日期:2023-02-27
通讯作者: * zhanghua.eye@163.com;caishanjun@163.com
基金资助:
京津冀基础研究合作专项项目(J200006)

Research progress on the role of IgG N-glycosylation modification in diabetic retinopathy

ZHANG Yixin¹, CAI Shanjun^1*, LI Zhili², YU Weihong³, ZHANG Hua^4*

1. Department of Ophthalmology, Affiliated Hospital of Zunyi Medical University, Zunyi 563003;
2. Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005;
3. Department of Ophthalmology, Peking Union Medical College Hospital;
4. College of Continuing Education, CAMS ＆ PUMC, Beijing 100730, China

Received:2022-04-02 Revised:2022-10-17 Online:2023-03-05 Published:2023-02-27
Contact: * zhanghua.eye@163.com;caishanjun@163.com

摘要/Abstract

摘要： 糖尿病视网膜病变(DR)是免疫炎性疾病,免疫球蛋白G(IgG) N-糖基化修饰与DR密切相关。其中,IgG的半乳糖基化修饰、岩藻糖基化修饰、唾液酸化和平分型N-乙酰葡糖胺修饰发生变化,导致机体处于促炎状态,诱导视网膜发生病变。

关键词: 糖尿病视网膜病变, 免疫球蛋白G, 糖基化修饰

Abstract: Diabetic retinopathy (DR) is an immune-inflammatory disease and immunoglobulin G(IgG) N-glycosylation modifications are closely associated with DR. Among them, the modification of galactosylation, fucosylation, sialylation and bisecting N-acetylglucosamine of IgG changed has been proved to be predisposing factor to stimulate inflammation and related retinopathy.

Key words: diabetic retinopathy, immunoglobulin G, glycosylation modification

中图分类号:

R774.1

张艺馨, 蔡善君, 李智立, 于伟泓, 张华. IgG N-糖基化修饰在糖尿病视网膜病变中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 509-513.

ZHANG Yixin, CAI Shanjun, LI Zhili, YU Weihong, ZHANG Hua. Research progress on the role of IgG N-glycosylation modification in diabetic retinopathy[J]. Basic & Clinical Medicine, 2023, 43(3): 509-513.

参考文献

[1]Lechner J, Medina RJ, Lois N, et al. Advances in cell therapies using stem cells/progenitors as a novel approach for neurovascular repair of the diabetic retina[J]. Stem Cell Res Ther, 2022,13:388. doi:10.1186/s13287-022-03073-x.
[2]Štambuk J, Nakić N, Vučković F, et al. Global varia-bility of the human IgG glycome[J]. Aging (Albany NY), 2020,12:15222-15259.
[3]Singh SS, Heijmans R, Meulen C, et al. Association of the IgG N-glycome with the course of kidney function in type 2 diabetes[J]. BMJ Open Diabetes Res Care, 2020,8. doi:10.1136/bmjdrc-2019-001026.
[4]Giblin MJ, Ontko CD, Penn JS. Effect of cytokine-induced alterations in extracellular matrix composition on diabetic retinopathy-relevant endothelial cell behaviors[J]. Sci Rep, 2022,12:12955. doi:10.1038/s41598-022-12683-7.
[5]Lessieur EM, Liu H, Saadane A, et al. Neutrophil-derived proteases contribute to the pathogenesis of early diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2021,62:7. doi:10.1167/iovs.62.13.7.
[6]Canataroglu H, Varinli I, Ozcan AA, et al. Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composi-tion of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy[J]. Ocul Immunol Inflamm, 2005,13:375-381.
[7]Yu H, Liu B, Wu G, et al. Dysregulation of circulating follicular helper T cells in type 2 diabetic patients with diabetic retinopathy[J]. Immunol Res, 2021,69:153-161.
[8]Wu Z, Pan H, Liu D, et al. Variation of IgG N-linked glycosylation profile in diabetic retinopathy[J]. J Diabetes, 2021,13:672-680.
[9]孙扬, 李琪欢, 田思佳, 等. 免疫球蛋白GN-糖基化与糖尿病视网膜病变的相关性研究[J]. 中国预防医学杂志, 2018,19:734-737.
[10]Adua E, Memarian E, Afrifa-Yamoah E, et al. N-glycosylation profiling of type 2 diabetes mellitus from baseline to follow-up: an observational study in a Ghanaian population[J]. Biomark Med, 2021,15:467-480.
[11]Wada R, Matsui M, Kawasaki N. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms[J]. MAbs, 2019,11:350-372.
[12]Aoyama M, Hashii N, Tsukimura W, et al. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies[J]. MAbs, 2019,11:826-836.
[13]Clauder AK, Kordowski A, Bartsch YC, et al. IgG Fc N-glycosylation translates MHCII haplotype into autoimmune skin disease[J]. J Invest Dermatol, 2021,141:285-294.
[14]Lu J, Chu J, Zou Z, et al. Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding[J]. Proc Natl Acad Sci U S A, 2015,112:833-838.
[15]Bournazos S, Vo H, Duong V, et al. Antibody fucosyla-tion predicts disease severity in secondary dengue infection[J]. Science, 2021,372:1102-1105.
[16]Ząbczyńska M, Polak K, Kozłowska K, et al. The contribution of IgG glycosylation to antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in Hashimoto's thyroiditis: an in vitro model of thyroid autoimmunity[J]. Biomolecules, 2020,10. doi:10.3390/biom10020171.
[17]Ohmi Y, Ise W, Harazono A, et al. Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis[J]. Nat Commun, 2016,7:11205. doi:10.1038/ncomms11205.
[18]Quevedo-Martínez JU, Garfias Y, Jimenez J, et al. Pro-inflammatory cytokine profile is present in the serum of Mexican patients with different stages of diabetic retinopathy secondary to type 2 diabetes[J]. BMJ Open Ophthalmol, 2021,6:e000717. doi:10.1136/bmjophth-2021-000717.
[19]Bartsch YC, Eschweiler S, Leliavski A, et al. IgG Fc sialylation is regulated during the germinal center reaction following immunization with different adjuvants[J]. J Allergy Clin Immunol, 2020,146:652-666.e11.
[20]Dotz V, Lemmers R, Reiding KR, et al. Plasma protein N-glycan signatures of type 2 diabetes[J]. Biochim Biophys Acta Gen Subj, 2018,1862:2613-2622.
[21]Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps[J]. Nat Genet, 2018,50:1505-1513.
[22]Irvine EB, Alter G. Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases[J]. Glycobiology, 2020,30:241-253.
[23]Nakano M, Mishra SK, Tokoro Y, et al. Bisecting GlcNAc is a general suppressor of terminal modification of N-glycan[J]. Mol Cell Proteomics, 2019,18:2044-2057.
[24]Rudman N, Kifer D, Kaur S, et al. Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG[J]. Diabetologia, 2022. doi:10.1007/s00125-022-05703-8.
[25]杜钰莹, 王悦, 赖治臻, 等. 肺癌与肺良性疾病特异血清免疫炎性蛋白质N-糖基化修饰差异[J]. 基础医学与临床, 2020,40:1096-1102.

IgG N-糖基化修饰在糖尿病视网膜病变中作用的研究进展

Research progress on the role of IgG N-glycosylation modification in diabetic retinopathy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	周悦, 林静娜. miR-199-3p通过靶向VegfA抑制大鼠糖尿病视网膜病变[J]. 基础医学与临床, 2023, 43(7): 1084-1089.
[2]	李晓娜, 齐先梅, 张田甜, 王婧. 沉默Fcgr3降低SiO₂诱导的小鼠肺泡巨噬细胞系MH-S炎性因子表达[J]. 基础医学与临床, 2023, 43(6): 904-908.
[3]	张梦瑶, 牛姝, 蔡静, 赵志刚, 周艳. miR-140-5p靶向HMGB1/IκB-α轴对糖尿病大鼠视网膜病变的影响[J]. 基础医学与临床, 2023, 43(4): 615-620.
[4]	王卉, 苏宪, 张赢赢, 褚战亚, 孙朝晖, 张金玲, 张倩倩. 异鼠李素减轻糖尿病视网膜病变大鼠视网膜细胞凋亡[J]. 基础医学与临床, 2023, 43(2): 265-270.
[5]	孙健茹, 仇文颖, 钱晓菁, 马超. Fc-gamma Ⅰ型受体在阿尔茨海默病患者和模型小鼠脑皮质的表达[J]. 基础医学与临床, 2022, 42(5): 740-744.